Barely a month after disappointing data shattered hopes for a major label expansion for the GI tumor drug Qinlock, Deciphera is making a major pivot — scrapping development plans for that drug and discarding another while it hunkers down and focuses on two remaining drugs in the pipeline. As a result, 140 of its staffers … Continue reading As lead drug runs into a wall, Deciphera slims down its pipeline, puts 140 jobs on the chopping block